Contents12 sections
Proviron is the brand name for mesterolone, an oral steroid made from dihydrotestosterone (DHT). Outside the United States it is still a prescription medicine for androgen deficiency in men, and it was once prescribed for male infertility. It has never been approved in the US. The trials behind it are mostly decades old and show weak or absent effects on fertility, no controlled trial has shown meaningful muscle gain, and the side effects are those expected from a DHT-type androgen: scalp, skin, prostate, blood lipids and suppression of natural testosterone.
In gyms, mesterolone has a different reputation. It gets described as a drug that hardens the look, frees up testosterone and keeps estrogen in check. Some of that comes from a real pharmacological quirk, its strong binding to sex hormone-binding globulin. Most of it has never been tested in the people who use it.
Key Takeaways
- Mesterolone is 1-alpha-methyl-DHT, an oral androgen that cannot convert to estrogen and is not 17-alpha-alkylated.
- It is approved in several countries for androgen deficiency in men. It has never been approved in the United States, where it is a scheduled anabolic steroid.
- Controlled trials in men with idiopathic infertility found no clear benefit on pregnancy rates, including a double-blind World Health Organization study.
- It binds sex hormone-binding globulin more avidly than DHT or testosterone, which is the basis for the claim that it frees up testosterone. The only human study to measure that found no rise in free testosterone.
- Its risks are androgenic: scalp hair loss in men prone to it, acne, prostate effects, worse blood lipids in animal studies and suppression of natural testosterone at higher doses.
What Is Proviron?
Proviron is the original brand name for mesterolone, developed by the German company Schering, now part of Bayer, and brought to market in the 1960s. It is sold as 25 mg tablets and remains available on prescription in a number of countries, but it has never been approved in the United States.
Chemically, mesterolone is dihydrotestosterone with a methyl group added at the carbon-1 position, which is why it is often written as 1-alpha-methyl-DHT. That methyl group slows the liver’s breakdown of the molecule enough for it to survive as a tablet. It is a different modification from the 17-alpha-alkylation found in oral steroids such as oxymetholone and stanozolol, and that difference matters for liver risk. Our mesterolone compound page goes deeper on the chemistry.
| Proviron at a Glance | Details |
|---|---|
| Generic name | Mesterolone (1-alpha-methyl-DHT) |
| Form | Oral tablets, 25 mg |
| Converts to estrogen | No |
| 17-alpha-alkylated | No |
| Approved medical use | Androgen deficiency in adult men (outside the US) |
| US regulatory status | Not FDA-approved; listed anabolic steroid under federal law |
| Sport | Prohibited by WADA at all times |
Where Mesterolone Is Still Prescribed
The European label gives the clearest picture of its approved use. The Spanish summary of product characteristics for Proviron 25 mg lists it as replacement therapy in adult men with androgen deficiency. The label dose there is 75 to 100 mg a day split across three or four doses for several months to start, then 50 to 75 mg a day for maintenance, with periodic testosterone checks. Those are approved label figures for supervised medical use, not figures for any other purpose.
The same label contraindicates it in androgen-dependent prostate cancer, in a PSA above 4 ng/mL, in benign prostatic hyperplasia, in past or present liver tumors, in male breast cancer and in women. Some national labels also still mention male infertility linked to hypogonadism, and that is the indication the trials treated least kindly.
How Mesterolone Works
Mesterolone binds the androgen receptor, the same target as testosterone and DHT. Because it is already a 5-alpha reduced steroid, aromatase cannot convert it to estradiol, and 5-alpha reductase cannot make it more potent. Finasteride and dutasteride, which block that enzyme, therefore do nothing to blunt its androgenic activity.
The weak muscle-building effect has a plausible mechanism. In a receptor binding study in Endocrinology, mesterolone bound the androgen receptor in skeletal muscle less avidly than methyltrienolone, nandrolone, methenolone or testosterone (PMID 6539197). DHT itself showed low muscle receptor binding in the same work, which the authors attributed to rapid conversion in muscle to metabolites that do not bind the receptor. That is rat and rabbit tissue, so the mechanism is a well-supported explanation rather than a measured human result.
The animal data is mixed: in adult chickens, four weeks of oral mesterolone increased muscle weight and caused hypertrophy in glycolytic fibers but not oxidative ones (PMID 34112889). No controlled trial has measured lean mass or strength in trained humans.
Does Proviron Free Up Testosterone?
This is the most repeated claim about Proviron, and it starts from something real. In the same Endocrinology work, mesterolone bound sex hormone-binding globulin more avidly than any other steroid tested, with a relative binding affinity roughly four times that of DHT (PMID 6539197). SHBG is the protein that carries most of the testosterone in blood, so a compound that occupies it should, in theory, displace testosterone and raise the free fraction.
Theory and measurement part company here. In a small cross-sectional study of 34 men treated for aging male syndrome with mesterolone 50 mg a day for two months, total testosterone, SHBG and estradiol all fell, and the free testosterone fraction rose while absolute free testosterone did not change significantly (PMID 25842579). That small, uncontrolled study is the closest thing to a direct test of the claim.
So the SHBG binding is documented and the downstream effect on usable free testosterone is not. No study has measured it in people also taking other anabolic steroids, which is the situation the claim is usually made about.
What the Clinical Studies Show
Most human research on mesterolone was done on fertility and mood in patients, not athletes, between the 1980s and the early 1990s.
Fertility
Four human studies point in much the same direction.
- A double-blind, randomized trial by the World Health Organization Task Force on the Diagnosis and Treatment of Infertility treated men for six months across seven centers. Cumulative pregnancy rates at eight months were 9% on placebo, 12% on the lower mesterolone dose and 16% on the higher dose, differences that did not reach significance (PMID 2680994).
- A 12-month double-blind, placebo-controlled trial in 52 men found a pregnancy rate of 26% on high-dose mesterolone against 48% on placebo. Motility and morphology improved on treatment, but they improved on placebo too (PMID 1900485).
- A randomized trial in 368 men compared nine months of mesterolone against vitamin C and found no difference in pregnancy rates in any subgroup (PMID 6398725).
- An open-label study of 250 men with idiopathic oligospermia reported improved sperm density and motility in moderate cases and 46% of partners becoming pregnant (PMID 2892728). With no control group, that figure cannot be separated from what would have happened anyway.
The controlled trials do not support mesterolone as a fertility treatment, and the one uncontrolled study that looks positive is the weakest of the four.
Libido and Mood
Two double-blind studies looked at mood in men, and they disagree. One compared mesterolone against amitriptyline in depressed men and found the two equally effective at reducing depressive symptoms, with fewer side effects on mesterolone (PMID 3880735). The other, a placebo-controlled study in 52 depressed men, found improvement during mesterolone treatment but no significant advantage over placebo (PMID 6431212). A case report describes mania in a previously mentally healthy person connected to mesterolone use (PMID 22926621).
The aging male study reported improved symptom scores, including in the sexual domain, but had no control group (PMID 25842579). Libido effects from androgens in deficient men are well established as a class. What has never been tested is whether adding mesterolone on top of other anabolic steroids improves libido, the main reason people say they use it.
What People Mean by a “Proviron Cycle”
There is no studied Proviron cycle. The phrase describes a pattern of use that circulates in forums and gym culture, not a protocol from any trial or label, and the figures attached to it online come from user reports rather than measurement.
What the phrase usually describes is mesterolone taken daily as a tablet alongside a testosterone base or a cutting stack, for as long as that stack runs. The reasons given are consistent: libido and well-being, a drier look at low body fat because mesterolone adds no estrogen-driven water, a hope of blunting estrogen side effects from the other compounds, and the fact that it is a tablet rather than another injection.
None of those effects has been measured in that setting. There is no controlled evidence that mesterolone burns fat, adds meaningful muscle, or makes other anabolic steroids work better. Muscle & Brawn reports what the published research shows and does not publish cycle plans or doses for non-medical use.
Proviron and Estrogen
Mesterolone cannot aromatize, so it adds no estrogen of its own. That is settled chemistry, and it is why mesterolone sits among the steroids that don’t cause gyno on their own. Gynecomastia and estrogen-driven water retention in a stack come from testosterone and other aromatizing compounds, not from mesterolone.
The bigger claim, that mesterolone actively controls estrogen by inhibiting aromatase, is not supported by good human data. The one measured observation that leans that way is the small aging male study, where estradiol fell alongside total testosterone and SHBG on mesterolone 50 mg a day (PMID 25842579). Falling estradiol there is just as consistent with less substrate, since the men’s own testosterone was being suppressed, as with any direct enzyme effect. No trial has tested mesterolone as an estrogen-control drug in men using other steroids.
Proviron Side Effects
Mesterolone’s risks are androgenic rather than estrogenic or hepatic, so it is milder than many oral steroids in some respects and no milder in others.
Hair Loss and Skin
Mesterolone acts directly on the androgen receptor, so it can accelerate male pattern hair loss in genetically susceptible men. Because it does not need 5-alpha reductase to be active, finasteride does not reduce its effect on the scalp. Our guide to steroids that don’t cause hair loss covers which compounds carry less of this risk.
Androgens also increase sebaceous gland activity, which can produce acne on the face, back and shoulders, most often in people who had significant acne as teenagers. That is an androgenic effect, not an estrogenic one.
Prostate
DHT is the principal androgen driving prostate growth, and mesterolone acts on the same receptor. The approved label treats this as a real risk, contraindicating the drug in androgen-dependent prostate cancer, in a PSA above 4 ng/mL and in benign prostatic hyperplasia, and warning that androgens can accelerate subclinical prostate cancer or benign enlargement.
In the small aging male study, prostate volume changed in both directions with no significant net change, and PSA did not change over two months (PMID 25842579). That is 34 men at label-range dosing over a short period, which says nothing about longer or heavier use. Claims that mesterolone has been shown to cause prostate cancer are not supported by the published evidence.
Cholesterol and Cardiovascular Risk
Oral androgens generally push HDL cholesterol down, and anabolic steroid use as a class is linked to worse lipid profiles. Mesterolone-specific human lipid data is sparse. In transgenic mice carrying a human-like lipoprotein system, mesterolone raised VLDL and LDL and blunted the HDL increase that exercise training produced (PMID 29058169). That is an animal study in a genetically modified model rather than a human risk estimate, but no human evidence puts mesterolone in a protected category.
Liver
The common claim that Proviron is liver-toxic like other oral steroids is not accurate as stated. Serious oral steroid hepatotoxicity is tied mainly to 17-alpha-alkylation, and mesterolone does not carry that modification.
Lower risk is not no risk. A published case report describes drug-induced liver injury attributed to mesterolone (PMID 31405534), and the European label contraindicates it in people with liver tumors. One case report cannot establish frequency, and there is little data on heavy or prolonged use.
Suppression of Natural Testosterone
Mesterolone is sometimes described as non-suppressive, but the evidence is dose-dependent. The European label states that mesterolone at the recommended dose does not impair spermatogenesis. In the open-label oligospermia study, it had no depressing effect on FSH and LH in men whose levels were normal or low, but suppressed them in about a quarter of men whose levels were elevated (PMID 2892728). A small 1986 study reported gonadotropin suppression in men with idiopathic oligospermia (PMID 3084373); only its title and journal record are indexed, so the size of that effect cannot be quoted.
At high doses, suppression is clear. In the placebo-controlled depression study, men taking 300 to 450 mg a day had significantly lower plasma testosterone and protein-bound testosterone during treatment (PMID 6431212). A rat study circulated online reports reduced sperm quality and lower sex hormone levels with mesterolone; it does not appear to be indexed in PubMed [VERIFY].
Recovery after stopping androgens is not specific to mesterolone. In a retrospective study of 641 men attending a UK clinic within three years of stopping anabolic steroids, only 48.2% had normalized luteinizing hormone, follicle-stimulating hormone and total testosterone, and the odds of recovery fell as the number of compounds used rose (PMID 38102386). Its authors describe post-cycle therapy as illicit, ill-defined and not recommended. Our page on PCT for testosterone covers that literature.
Women
Mesterolone is contraindicated in women on its approved label. Virilization signs reported with androgens as a class include voice deepening, facial and body hair growth, clitoral enlargement, acne and menstrual disruption. Voice deepening and clitoral enlargement may not reverse after stopping.
Proviron vs Masteron
Mesterolone is most often compared with Masteron, the brand name for drostanolone. Both are methylated DHT derivatives that cannot convert to estrogen, both carry DHT-type androgenic side effects, and neither is a mass builder. They differ in form, approved history and receptor binding.
| Proviron | Masteron | |
|---|---|---|
| Compound | Mesterolone (1-alpha-methyl-DHT) | Drostanolone (2-alpha-methyl-DHT) |
| Form | Oral tablets | Injectable esters (propionate, enanthate) |
| Approved medical use | Androgen deficiency in men, outside the US | Advanced breast cancer in women, largely withdrawn |
| Converts to estrogen | No | No |
| 17-alpha-alkylated | No | No |
| Muscle effect | Weak in receptor binding studies | No controlled human data |
| Hair loss and prostate risk | Present (DHT derivative) | Present (DHT derivative) |
| WADA status | Prohibited at all times | Prohibited at all times |
Legal Status and Anti-Doping
United States. Mesterolone is not FDA-approved, and it is named in the federal definition of an anabolic steroid at 21 U.S.C. 802(41)(A)(xxi), which places it in Schedule III. There is no legal prescription route to it in the US.
Elsewhere. Proviron remains a prescription medicine in a number of countries, including several in Europe. In the UK, anabolic steroids are Class C drugs: possession for personal use is not an offense, but supply and importation are.
Sport. Mesterolone is an anabolic androgenic steroid under section S1.1 of the WADA Prohibited List and is banned at all times, in and out of competition.
Product quality. A meta-analysis of 5,413 black-market anabolic steroid samples found a mean 36% counterfeit and a further 37% substandard (PMID 35842594), so tablets sold as Proviron outside a pharmacy are often not what the label says.
A Current Case: Bozhidar Andreev
On November 6, 2026, the International Testing Agency reported that Bulgarian weightlifter Bozhidar Dimitrov Andreev had been sanctioned with four years of ineligibility after a mesterolone metabolite was found in a sample collected in an out-of-competition test on October 15, 2025. The ban runs from November 18, 2025 to November 17, 2029, and his results from October 15 to November 18, 2025 were disqualified. The ITA issued the decision in writing on behalf of the International Weightlifting Federation, a route used when an athlete does not contest the violation or request a hearing. It can be appealed to the Court of Arbitration for Sport.
The Bottom Line
Mesterolone is a real prescription androgen with a thin evidence base, a weak effect on muscle and a fully androgenic side effect profile, and most of what it is known for in gyms has never been tested.
- Controlled trials in men with idiopathic infertility, including a double-blind World Health Organization study, found no clear benefit on pregnancy rates.
- Its strong SHBG binding is documented, but the only human study to measure the downstream effect found no rise in free testosterone.
- The supported risks are androgenic: hair loss in susceptible men, acne, prostate effects, worse lipids in animal models, and dose-dependent suppression of natural testosterone.
- It is not FDA-approved, it is Schedule III in the US, and it is banned in sport at all times, with a four-year ban issued for it in November 2026.
Frequently Asked Questions
Disclaimer
Please read carefully
Not medical advice
Content here is not a substitute for professional medical advice.
Consult your doctor
Talk to your doctor before starting any supplement or new routine.
Use at your own risk
We are not responsible for adverse effects from acting on this.
Do your research
Make informed decisions about your own health.
No guarantees
Individual results vary. No claims about outcomes.
Important — Never disregard professional medical advice or delay seeking it because of something you read here. If you think you may have a medical emergency, call your doctor or your local emergency number right away.



